Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Apr;45(4):969-79.
doi: 10.1183/09031936.00136014. Epub 2015 Jan 8.

Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)

Roland Buhl  1 , François Maltais  2 , Roger Abrahams  3 , Leif Bjermer  4 , Eric Derom  5 , Gary Ferguson  6 , Matjaž Fležar  7 , Jacques Hébert  8 , Lorcan McGarvey  9 , Emilio Pizzichini  10 , Jim Reid  11 , Antony Veale  12 , Lars Grönke  13 , Alan Hamilton  14 , Lawrence Korducki  15 , Kay Tetzlaff  16 , Stella Waitere-Wijker  17 , Henrik Watz  18 , Eric Bateman  19
Affiliations
Clinical Trial

Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)

Roland Buhl et al. Eur Respir J. 2015 Apr.

Erratum in

Abstract

Efficacy and safety of tiotropium+olodaterol fixed-dose combination (FDC) compared with the mono-components was evaluated in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in two replicate, randomised, double-blind, parallel-group, multicentre, phase III trials. Patients received tiotropium+olodaterol FDC 2.5/5 μg or 5/5 μg, tiotropium 2.5 μg or 5 μg, or olodaterol 5 μg delivered once-daily via Respimat inhaler over 52 weeks. Primary end points were forced expiratory volume in 1 s (FEV1) area under the curve from 0 to 3 h (AUC0-3) response, trough FEV1 response and St George's Respiratory Questionnaire (SGRQ) total score at 24 weeks. In total, 5162 patients (2624 in Study 1237.5 and 2538 in Study 1237.6) received treatment. Both FDCs significantly improved FEV1 AUC0-3 and trough FEV1 response versus the mono-components in both studies. Statistically significant improvements in SGRQ total score versus the mono-components were only seen for tiotropium+olodaterol FDC 5/5 μg. Incidence of adverse events was comparable between the FDCs and the mono-components. These studies demonstrated significant improvements in lung function and health-related quality of life with once-daily tiotropium+olodaterol FDC versus mono-components over 1 year in patients with moderate to very severe COPD.

Trial registration: ClinicalTrials.gov NCT01431274 NCT01431287.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Disclosures can be found alongside the online version of this article at erj.ersjournals.com

Figures

FIGURE 1
FIGURE 1
Study design (Study 1237.5: NCT01431274; Study 1237.6: NCT0143 1287). R: randomisation; FDC: fixed- dose combination. #: primary end-point assessment.
FIGURE 2
FIGURE 2
Patient disposition and flow in (a) Study 1237.5 and (b) Study 1237.6. Tio: tiotropium; Olo: olodaterol; FDC: fixed-dose combination. #: not due to adverse event.
FIGURE 3
FIGURE 3
Lung function end points (combined data set) over 52 weeks: full analysis set. a) adjusted mean trough forced expiratory volume in 1 s (FEV1); all comparisons of Tio+Olo 5/5 μg and 2.5/5 μg versus the monotherapies were statistically significant (p<0.001). b) FEV1 area under the curve from 0 to 3 h (AUC0–3); all comparisons of Tio+Olo 5/5 μg and 2.5/5 μg versus the monotherapies were statistically significant (p<0.01). Tio: tiotropium; Olo: olodaterol.
See this image and copyright information in PMC

Comment in

References

    1. Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res 2013; 14: 49. - PMC - PubMed
    1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2014. www.goldcopd.org/uploads/users/files/GOLD_Report2014_Feb07.pdf Date last updated: 2014. Date last accessed: 2 June 2014. - PubMed
    1. Tashkin DP, Celli B, Senn S, et al. , for the UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543–1554. - PubMed
    1. Bateman ED, Tashkin D, Siafakas N, et al. . A one-year trial of tiotropium Respimat® plus usual therapy in COPD patients. Respir Med 2010; 104: 1460–1472. - PubMed
    1. Cooper CB, Celli BR, Jardim JR, et al. . Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial. Chest 2013; 144: 490–497. - PubMed

Publication types

MeSH terms

Associated data